COMP <GO>
KURA vs RIGL // NET PROFIT MARGIN
Kura Oncology Inc. (NASDAQ) VS. Rigel Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KURA 0
— RIGL 9
▲ NET PROFIT MARGIN LEADER: RIGL
LAST: $10.56 (-1.49%) • MKT CAP: $939.4M
net-margins
-60.00%
LAST: $51.45 (+1.40%) • MKT CAP: $961.1M
net-margins
68.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KURA VS. RIGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KURA | RIGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 93.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 28.20% | -63.20 | RIGL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.53% | 7.87% | -15.40 | RIGL | /fcf-yield <GO> |
| Operating Margin | -60.00% | 42.60% | -102.60 | RIGL | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | 68.00% | -128.00 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) | 25.20% | 64.10% | -38.90 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.64 | -3.44 | RIGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | RIGL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 64.9 | -11.80 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $939.4M | $961.1M | -$21.7M | RIGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KURA REV | RIGL REV | KURA GROSS % | RIGL GROSS % | KURA FCF | RIGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $67.5M | $294.3M | — | 93.3% | -$70.7M | $75.7M |
| FY 2024 | $53.9M | $179.3M | — | 89.6% | $133.8M | $31.5M |
| FY 2023 | $0 | $116.9M | — | — | -$124.8M | -$5.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KURA // BETA —
RIGL // BETA —